Follistatin vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
FollistatinFat Loss & Metabolic
5-Amino-1MQ- Summary
- Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- ~3–5 hours (endogenous form)
- Estimated 4–8 hours
- Admin Route
- IM, SubQ
- Oral
- Research
- —
- —
- Typical Dose
- 50–100 mcg per injection site
- 50–100 mg
- Frequency
- Every other day or 2–3x per week
- Once to twice daily
- Key Benefits
- Potent myostatin inhibition enabling supraphysiological muscle growth
- Increases skeletal muscle mass and fiber size
- May accelerate recovery from muscle injury
- Potential benefits in muscular dystrophy and sarcopenia
- Synergistic with IGF-1 and growth hormone in anabolic protocols
- Animal studies show dramatic increases in muscle mass
- Reduces muscle fibrosis in dystrophic models
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Potential for excessive muscle growth if doses are not controlled
- FSH suppression with implications for fertility in women
- Theoretical risk of cardiac hypertrophy with prolonged high-dose use
- Limited human safety data available
- +1 more
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —